secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2022-02-25T23:59:59+00:00
Accession:  0000320017-22-000008
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Caladrius Biosciences Chief Legal Officer Todd Girolamo resigns effective March 14
--------------------------------------------------------------------------------

- Todd Girolamo resigns as Chief Legal Officer, SVP Corporate Development, and Corporate Secretary.
- Resignation effective March 14, 2022; reason is to pursue other career opportunities.
- No replacement named as of the filing date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001722000008/0000320017-22-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001722000008/clbs-20220224.htm
  HTML page:      https://secwatch.observer/filing/0000320017-22-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer